Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744261 | 1.00 | CYP1A2 (0.52) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL1595084 | 1.00 | CYP1A2 (0.52) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL1744263 | 1.00 | CYP1A2 (0.52) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL1595082 | 1.00 | CYP1A2 (0.52) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL1742683 | 0.87 | CYP1A2 (0.57) | CYP1A2HDAC3ADAM17HDAC1HDAC2 | |
| SCHEMBL24740553 | 0.84 | CYP1A2 (0.55) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL12650395 | 0.84 | CYP1A2 (0.50) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL9967716 | 0.84 | CYP1A2 (0.50) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL9059052 | 0.81 | CYP1A2 (0.47) | CYP1A2PTGS1NQO2CA1CA2 | |
| SCHEMBL24434695 | 0.81 | CYP1A2 (0.47) | CYP1A2PTGS1NQO2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7919504-B2 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-2167504-A2 | THIADIAZOLE MODULATORS OF PKB | Amgen, Inc (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2009011871-A2 | THIADIAZOLE MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | CYP1A2 2590/4885PTGS1 402/4885NQO2 662/4885 |
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | CYP1A2 1923/4885PTGS1 365/4885NQO2 1295/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CYP1A2 2492/4885PTGS1 694/4885NQO2 1023/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CYP1A2 2229/4885PTGS1 301/4885NQO2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.